198 related articles for article (PubMed ID: 9435198)
1. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin.
Ferguson RJ; De Morais SM; Benhamou S; Bouchardy C; Blaisdell J; Ibeanu G; Wilkinson GR; Sarich TC; Wright JM; Dayer P; Goldstein JA
J Pharmacol Exp Ther; 1998 Jan; 284(1):356-61. PubMed ID: 9435198
[TBL] [Abstract][Full Text] [Related]
2. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin.
Ibeanu GC; Goldstein JA; Meyer U; Benhamou S; Bouchardy C; Dayer P; Ghanayem BI; Blaisdell J
J Pharmacol Exp Ther; 1998 Sep; 286(3):1490-5. PubMed ID: 9732415
[TBL] [Abstract][Full Text] [Related]
3. An additional defective allele, CYP2C19*5, contributes to the S-mephenytoin poor metabolizer phenotype in Caucasians.
Ibeanu GC; Blaisdell J; Ghanayem BI; Beyeler C; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Daly AK; Goldstein JA
Pharmacogenetics; 1998 Apr; 8(2):129-35. PubMed ID: 10022751
[TBL] [Abstract][Full Text] [Related]
4. CYP2C19 genotype and S-mephenytoin 4'-hydroxylation phenotype in a Chinese Dai population.
He N; Yan FX; Huang SL; Wang W; Xiao ZS; Liu ZQ; Zhou HH
Eur J Clin Pharmacol; 2002 Apr; 58(1):15-8. PubMed ID: 11956668
[TBL] [Abstract][Full Text] [Related]
5. S-mephenytoin hydroxylation phenotype and CYP2C19 genotype among Ethiopians.
Persson I; Aklillu E; Rodrigues F; Bertilsson L; Ingelman-Sundberg M
Pharmacogenetics; 1996 Dec; 6(6):521-6. PubMed ID: 9014201
[TBL] [Abstract][Full Text] [Related]
6. A multifamily study on the relationship between CYP2C19 genotype and s-mephenytoin oxidation phenotype.
Brøsen K; de Morais SM; Meyer UA; Goldstein JA
Pharmacogenetics; 1995 Oct; 5(5):312-7. PubMed ID: 8563772
[TBL] [Abstract][Full Text] [Related]
7. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.
De Morais SM; Wilkinson GR; Blaisdell J; Meyer UA; Nakamura K; Goldstein JA
Mol Pharmacol; 1994 Oct; 46(4):594-8. PubMed ID: 7969038
[TBL] [Abstract][Full Text] [Related]
8. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype.
Chang M; Dahl ML; Tybring G; Götharson E; Bertilsson L
Pharmacogenetics; 1995 Dec; 5(6):358-63. PubMed ID: 8747407
[TBL] [Abstract][Full Text] [Related]
9. Genetic variations of S-mephenytoin 4'-hydroxylase (CYP2C19) in the Chinese population.
Xie HG
Life Sci; 2000 Feb; 66(14):PL175-81. PubMed ID: 10755474
[TBL] [Abstract][Full Text] [Related]
10. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19.
Bertilsson L
Clin Pharmacokinet; 1995 Sep; 29(3):192-209. PubMed ID: 8521680
[TBL] [Abstract][Full Text] [Related]
11. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations.
Goldstein JA; Ishizaki T; Chiba K; de Morais SM; Bell D; Krahn PM; Evans DA
Pharmacogenetics; 1997 Feb; 7(1):59-64. PubMed ID: 9110363
[TBL] [Abstract][Full Text] [Related]
12. A novel transversion in the intron 5 donor splice junction of CYP2C19 and a sequence polymorphism in exon 3 contribute to the poor metabolizer phenotype for the anticonvulsant drug S-mephenytoin.
Ibeanu GC; Blaisdell J; Ferguson RJ; Ghanayem BI; Brosen K; Benhamou S; Bouchardy C; Wilkinson GR; Dayer P; Goldstein JA
J Pharmacol Exp Ther; 1999 Aug; 290(2):635-40. PubMed ID: 10411572
[TBL] [Abstract][Full Text] [Related]
13. [The molecular mechanism of polymorphism of S-mephenytoin hydroxylative metabolism].
Lou YQ; Kuang TY
Sheng Li Ke Xue Jin Zhan; 1995 Jan; 26(1):23-8. PubMed ID: 7604218
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population.
Sviri S; Shpizen S; Leitersdorf E; Levy M; Caraco Y
Clin Pharmacol Ther; 1999 Mar; 65(3):275-82. PubMed ID: 10096259
[TBL] [Abstract][Full Text] [Related]
15. Bantu Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype.
Herrlin K; Massele AY; Jande M; Alm C; Tybring G; Abdi YA; Wennerholm A; Johansson I; Dahl ML; Bertilsson L; Gustafsson LL
Clin Pharmacol Ther; 1998 Oct; 64(4):391-401. PubMed ID: 9797796
[TBL] [Abstract][Full Text] [Related]
16. Differences in the incidence of the CYP2C19 polymorphism affecting the S-mephenytoin phenotype in Chinese Han and Bai populations and identification of a new rare CYP2C19 mutant allele.
Xiao ZS; Goldstein JA; Xie HG; Blaisdell J; Wang W; Jiang CH; Yan FX; He N; Huang SL; Xu ZH; Zhou HH
J Pharmacol Exp Ther; 1997 Apr; 281(1):604-9. PubMed ID: 9103550
[TBL] [Abstract][Full Text] [Related]
17. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans.
de Morais SM; Wilkinson GR; Blaisdell J; Nakamura K; Meyer UA; Goldstein JA
J Biol Chem; 1994 Jun; 269(22):15419-22. PubMed ID: 8195181
[TBL] [Abstract][Full Text] [Related]
18. Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-->A-splice site mutation.
Brockmöller J; Rost KL; Gross D; Schenkel A; Roots I
Pharmacogenetics; 1995 Apr; 5(2):80-8. PubMed ID: 7663532
[TBL] [Abstract][Full Text] [Related]
19. Genetic analysis of the S-mephenytoin polymorphism in a Chinese population.
de Morais SM; Goldstein JA; Xie HG; Huang SL; Lu YQ; Xia H; Xiao ZS; Ile N; Zhou HH
Clin Pharmacol Ther; 1995 Oct; 58(4):404-11. PubMed ID: 7586932
[TBL] [Abstract][Full Text] [Related]
20. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population.
Tassaneeyakul W; Tawalee A; Tassaneeyakul W; Kukongviriyapan V; Blaisdell J; Goldstein JA; Gaysornsiri D
Pharmacogenetics; 2002 Apr; 12(3):221-5. PubMed ID: 11927837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
